CAS · 149690-05-1
Product Overview
Sacubitril Sodium is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | White or off-white powder |
|---|---|
| Assay: | 98.0%~102.0% (anhydrous substance) |
| Identification: | Retention Time: Similar to Reference Substance IR: Similar to Reference Substance This product shows the flame reaction of sodium salt The X-ray diffraction patterns have peaks at 2 theta: 6.2°±0.2°, 19.9°±0.2°, 21.5°±0.2° |
| Na: | 4.1%~6.5% (anhydrous substance) |
| Water: | 5.0% max |
Applications
1. Pharmaceutical Use in Heart Failure Management
Sacubitril Sodium is combined with valsartan (an angiotensin receptor blocker) to form Entresto, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI).
Indicated for treatment of chronic heart failure with reduced ejection fraction (HFrEF).
Improves heart function by:
Enhancing natriuretic peptide levels (vasodilation, natriuresis, diuresis).
Reducing cardiac remodeling and fibrosis.
Lowering blood pressure.
Clinical trials show it reduces mortality and hospitalization rates in heart failure patients.
2. Research and Drug Development
Used as a key chemical in studies exploring neprilysin inhibition and cardiovascular pharmacology.
Serves as a reference compound for developing new ARNI drugs or similar cardiovascular agents.
Benefits
Improves clinical outcomes in heart failure patients when combined with valsartan.
Provides a dual mechanism of action (neprilysin inhibition + RAAS blockade).
Helps reduce symptoms and risk of hospitalization.
Represents a significant advancement over traditional heart failure therapies.
Conclusion
A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.